Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: pappy who wrote (550)	4/27/1998 4:15:00 AM
From: Jim Mac	Read Replies (1) \| Respond to of 1754

All this nonsense about how Nidek, LaserSight, and others will undermine the per-procedure fee by charging, perhaps, NO fees (MrGeneral on Yahoo board) misses one important fact: The only way for the manufacturer/patent holder to make money is to charge fees for use. It's a cost of doing business for the centers. ALL manufacturers will charge procedure royalties in U.S. and Japan, the two biggest markets in the world in the near-term. Nidek, Autonomous, Visx, everyone. People need to quit fantasizing about the end of procedure fees. It won't happen in the major markets. And these lawsuits are just last-ditch effort money-grabs by people with nothing to lose. Besides, Summit and Visx are "deep-pockets" now, and all this FTC nonsense is giving these yahoo's the green light to stomp on the lawsuit accelerator while time is still ripe.